# Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma

> **NCT00189137** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 84 (actual)

## Conditions studied

- Sarcoma, Soft Tissue

## Interventions

- **DRUG:** ifosfamide and doxorubicin vs gemcitabine and docetaxel

## Key facts

- **NCT ID:** NCT00189137
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-08
- **Primary completion:** 2012-11
- **Final completion:** 2015-10
- **Target enrollment:** 84 (ACTUAL)
- **Last updated:** 2015-12-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00189137

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00189137, "Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-10 from https://api.ai-analytics.org/clinical/NCT00189137. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*